Меню
КартаВръзкиТемиБългарияНощта (K-TRIO)Мария Склодовска-КюриЗа ученициЗа учителиМетодологияИзненадай ме
H2020Докторантска мрежа2018–2023

EVOdrops · directed EVOlution in DROPS

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период
2018-10-01 → 2023-09-30
Финансиране от ЕС
3 452 423 €
Участници
19
Схема
MSCA-ITN

Линиите свързват координатора с партньорите.

Накратко на български

Насочената еволюция в микрофлуидни капки позволява бързото създаване и подбор на по-ефективни ензими за индустриални процеси. Това ускорява подобряването на химически, фармацевтични и земеделски продукти, което естествената еволюция би постигнала твърде бавно.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

directed EVOlution in DROPS

The bio-economy is poised for substantial growth, with projections indicating that by 2030, biotechnological production will contribute significantly to various sectors. Estimates suggest a substantial presence, such as 35% in chemical and industrial products, 80% in pharmaceutical and diagnostic production, and 50% in agricultural output. Industries, continually seeking process and product enhancements, face challenges in natural evolution's slow pace. Natural processes, including Darwinian evolution, optimize proteins in response to environmental pressures over billions of years. Enzymes, as nature's catalysts, play vital roles in diverse cellular reactions. While some natural enzymes hold industrial promise, relying on natural evolution for their improvement has drawbacks: limited control over selection pressures and inability to enhance non-natural systems. Directed evolution, mimicking nature's principles in the laboratory, addresses these limitations. Unlike the lengthy natural evolution, directed evolution combines rapid genetic diversity generation, ultra-high throughput screening, and selection for efficient industrial processes. Microfluidics, a versatile technology, integrates into industrial processes, employing droplets as micro-reactors in miniaturized, automated assays. This enables ultra-high-throughput screening, reducing reagent costs and facilitating experiments impossible with other techniques. The microfluidic market has witnessed impressive growth, driven by start-ups and industrial giants entering the sector. The technology's potential applications in diagnostics, healthcare, and bio-resource transformation contribute to its expanding market. In a later project phase, Artificial Intelligence (AI) emerged as a crucial element. Recognizing AI's potential in microfluidics and directed evolution, the EVOdrops project incorporated it. AI, applied in health and medical fields for early diagnosis and personalized medicine, extends its utility to other industrially important molecules. The convergence of AI with micro-/acoustofluidics expands the EVOdrops portfolio, emphasizing the interdisciplinary approach for enhanced outcomes. This integration aligns with the evolving landscape of technological development, with AI gaining prominence during the pandemic. The recognition of AI's significant potential prompted its inclusion in the EVOdrops program, showcasing a dynamic response to technological advancements.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Natural evolution is a powerful process that has given rise to the functionally diverse set of proteins present in all living systems. Repetitive rounds of mutation, selection and amplification have optimised nature’s catalysts, the enzymes, to perform an enormous range of different reactions. However, natural evolution has driven the optimisation of enzymes subjected to living functions of microorganisms, according to ill-defined and fluctuating external conditions and is not suitablefor industrial processes since it lacks of control of selection pressure. In EVOdrops, we will use directed evolution to overcome these limitations. It is a synthetic, man-made approach of evolution, aiming at improving living systems based on predefined needs, controlling the external selection pressure. While natural evolution took billions of years to optimisemacromolecules, directed evolution – to be efficient in an industrial process – requires both the generation of genetic diversity and ultra-high throughput screening capabilities to recover the variants of interest. We will develop and optimise these tools using the ground-breaking potential of droplet-based microfluidics for high-throughput experimentation and thefine control of gene library construction. EVOdrops, a European training network, will bring together the leading research scientists, laboratories and industries in Europe with outstanding expertise in protein engineering and microfluidics and 13 early stage researchers. We will offer an extensive multi- and interdisciplinary training to ensure that they can solve these urgent and unmet challenges in biotechnology and biomedicine. We will use a multidisciplinary approach combining soft matter, microfluidics and chemical biology to design solutions for the selection of new enzymes of industrial and therapeutic interest. In the future, our approaches can be generalised to challenges involving high-throughput miniaturised biochemical or cell-based assays.

Оригинален текст от CORDIS (на английски).

Участници

Връзки

Данни: CORDIS, © Европейски съюз